Vijayvel Jayaprakash

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · Oral Oncology · 2018 · 800 citations · Full text

Medicine, Oncology, Metastasis +14

Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case‐control studies from 27 countries

David I. Conway, Darren R. Brenner, Alex D. McMahon et al. · International Journal of Cancer · 2014 · 165 citations · Full text

Public Health, Health Education, Oncology +13

Survival rates and prognostic factors for infiltrating salivary duct carcinoma: Analysis of 228 cases from the Surveillance, Epidemiology, and End Results database

Vijayvel Jayaprakash, Mihai Merzianu, Graham Warren et al. · Head & Neck · 2013 · 150 citations · Full text

Dentistry, Oncology, Cancer Epidemiology +14

A Randomized Double-Blind Placebo-Controlled Phase IIB Trial of Curcumin in Oral Leukoplakia

Moni Abraham Kuriakose, Kunnambath Ramdas, Bindu Dey et al. · Cancer Prevention Research · 2016 · 98 citations

Dentistry, Oncology, Oral Medicine +15

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Robert I. Haddad, Fernando Concha‐Benavente, George R. Blumenschein et al. · Cancer · 2019 · 98 citations · Full text

Medicine, Oncology, Pharmacotherapy +16